Monitor pricing terms (interest rate, conversion price) to gauge dilution impact and market reception. The offering extends cash runway but adds convertible debt that could be dilutive; watch for potential insider selling or further dilution if stock trades near conversion price.
OCGN drugs
OCGN drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 5 $1.49entry
- T+1 · 7mo ago 0.00%α −1.38% · $1.49
- T+5 · 6mo ago −0.67%α −2.66% · $1.48
- T+20 · 6mo ago −10.07%α −15.02% · $1.34
- T+60 · 4mo ago −15.44%α −18.18% · $1.26
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Ocugen announced a private offering of $115M convertible senior notes due 2034 (plus $15M option), intending to use ~$32.7M to repay existing Avenue loan and the remainder for general corporate purposes. The filing also provides preliminary cash of $32.2M as of March 31, 2026. This capital raise extends runway but introduces dilution overhang.
Key Facts
- Private offering of $115M aggregate principal amount of convertible senior notes due 2034
- Initial purchaser granted 13-day option to purchase up to an additional $15M of notes
- Approximately $32.7M of net proceeds to fully repay Avenue Loan Agreement
- Preliminary cash, cash equivalents, and restricted cash of ~$32.2M as of March 31, 2026
- 338,318,899 shares of common stock outstanding as of March 31, 2026
Financial Impact
$115M gross proceeds; net of ~$32.7M debt repayment and fees, net proceeds ~$80M+; prior cash $32.2M
Risk Factors
- Potential dilution upon conversion of notes
- Uncertainty in market conditions may alter offering terms
- Conversion price and interest rate not yet determined
- Pre-revenue biotech with ongoing cash burn
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-054866 |
| Document: tm2613474d1_ex99-1.htm | 0001104659-26-054866 |
| Document: tm2613474d1_ex99-2.htm | 0001104659-26-054866 |
| Document: 0001104659-26-054866-index-headers.html | 0001104659-26-054866 |
| Document: 0001104659-26-054866-index.html | 0001104659-26-054866 |
| Document: 0001104659-26-054866.txt | 0001104659-26-054866 |
| 8-K Data (Synthetic) | 0001104659-26-054866 |
Track record
23 reports on OCGN
3 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +20.49% at T+20 after the Jun 11, 2026 report. 4 of 6 went positive at some point.
Filters
- Nov 10, 20266d ago 8-K Neutral 4/10 Entry $0.9500 to $0.9604 Now $0.7730 −18.63% ▲ +1.09% −0.22% vs SPY
- Nov 10, 20266d ago Press Release Neutral 4/10 Entry $0.9500 to $0.9604 Now $0.7730 −18.63% ▲ +1.09% −0.22% vs SPY
- Nov 6, 202610d ago DEFA14A Neutral 2/10 Entry $0.9721 to $0.9500 Now $0.7730 −20.48% ▼ −2.27% −1.91% vs SPY
- Nov 6, 202610d ago DEFA14A Neutral 3/10 Entry $0.9721 to $0.9500 Now $0.7730 −20.48% ▼ −2.27% −1.91% vs SPY
- Nov 4, 202612d ago 8-K Neutral 4/10 No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $0.8745 to $0.8165 Now $0.7730 −11.61% ▼ −6.63% −2.22% vs SPY
- Oct 15, 20264w ago 8-K Neutral 5/10 Entry $0.8137 to $0.7803 Now $0.7730 −5.00% ▼ −4.10% −3.00% vs SPY
- Oct 14, 20264w ago 8-K Mixed 5/10 Entry $0.8137 to $0.7803 Now $0.7730 −5.00% ▼ −4.10% −3.00% vs SPY
- Oct 9, 20265w ago 144 Neutral 2/10 Entry $0.9472 to $0.8854 Now $0.7730 −18.39% ▼ −6.52% −6.51% vs SPY
- Sep 1, 202610w ago Press Release Bullish 7/10 Entry $1.33 to $1.32 Now $0.7730 −41.88% ▼ −0.75% −1.20% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers